Bolt Biotherapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
02/08/2024 13:49
* Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected
to show
a fall in quarterly revenue when it reports results on August 5
(estimated) for the period ending June 30 2024
* The Redwood City California-based company is expected to
report
a 37.8% decrease in revenue to $891.5 thousand from $1.43
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Bolt Biotherapeutics Inc
is
for a loss of 48 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $1.25, above its last closing price
of $0.74.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.50 -0.51 -0.28 Beat 45.1
Jan. 1 2024 -0.44 -0.48 -0.47 Beat 2.4
Jan. 1 0001 -0.50 -0.50 -0.43 Beat 14
Jun. 30 2023 -0.50 -0.49 -0.48 Beat 1.4
Mar. -0.51 -0.51 -0.45 Beat 12.1
31 2023
Dec. 31 2022 -0.60 -0.53 Beat 11.4
Sep. 30 2022 -0.56 -0.56 -0.58 Missed -3
Jun. 30 2022 -0.69 -0.68 -0.61 Beat 10
This summary was machine generated August 2 at 12:49 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)